drugset / Trial / NCT06933563
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
Phase 0
Not yet recruiting
18 enrolled
Zhejiang University
Shanghai Xiniao Biotech Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Myasthenia gravis. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.
Timeline
- Start
- 2025-04
- Primary completion
- 2026-04
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UCAR T-cells | Cell therapy | — | Intravenous |